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Abstract
Background: Antimicrobial peptides (AMP) are important effectors of the innate immune system.
Although there is increasing evidence that AMPs influence bacteria in a multitude of ways, bacterial
wall rupture plays the pivotal role in the bactericidal action of AMPs. Structurally, AMPs share many
similarities with endogenous heparin-binding peptides with respect to secondary structure,
cationicity, and amphipathicity.
Findings: In this study, we show that RQA21 (RQAREHSERKKRRRESECKAA), a cationic and
hydrophilic heparin-binding peptide corresponding to the C-terminal region of extracellular
superoxide dismutase (SOD), exerts antimicrobial activity against Escherichia coli, Pseudomonas
aeruginosa, Staphylococcus aureus, Bacillus subtilis and Candida albicans. The peptide was also found to
induce membrane leakage of negatively charged liposomes. However, its antibacterial effects were
abrogated in physiological salt conditions as well as in plasma.
Conclusion:  The results provide further evidence that heparin-binding peptide regions are
multifunctional, but also illustrate that cationicity alone is not sufficient for AMP function at
physiological conditions. However, our observation, apart from providing a link between heparin-
binding peptides and AMPs, raises the hypothesis that proteolytically generated C-terminal SOD-
derived peptides could interact with, and possibly counteract bacteria. Further studies are
therefore merited to study a possible role of SOD in host defence.
Background
Antimicrobial peptides (AMP) are short cationic peptides
widely distributed at biological surfaces prone to infec-
tion, playing important roles in innate immunity [1]. At
present at least 900 different AMP have been discovered
http://www.bbcm.univ.trieste.it/~tossi/search.htm. Many
AMPs are characterized by an amphipathic structure,
where clusters of hydrophobic and cationic amino acids
are spatially organized in sectors within the molecules.
For example, AMPs comprise linear peptides, many of
which may adopt α-helical and amphipathic conforma-
tion upon bacterial binding, peptides forming cysteine-
linked antiparallel β-sheets, as well as cysteine-con-
strained loop structures. AMPs may also, however, be
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found among peptides not displaying such ordered struc-
tures as long as these are characterized by an over-repre-
sentation of certain amino acids [1]. Considering the role
of peptide secondary structure and amphphilicity, as well
as the composition of bacterial membranes, AMP func-
tion has been thought to involve direct binding to the
lipid bilayer, and the interaction with bacterial mem-
branes is a prerequisite for AMP function. However, the
modes of action of AMPs on their target bacteria are com-
plex, and can be divided into membrane disruptive and
non-membrane disruptive [1,2]. Nevertheless, the lack of
a specific molecular microbial target minimizes the risk of
resistance development and thus AMPs may have thera-
peutic potential [3].
Superoxide dismutase (SOD) is a metalloenzyme that cat-
alyzes the dismutation of superoxide radicals [4]. Mam-
malian cell produce two different types of SOD, one
intracellular and one extracellular form. Extracellular
superoxide dismutase (EC-SOD) is the major form (>90%
of total), present in all extracellular fluids, including
plasma, lymph, synovial fluid, brain grey matter, liver,
kidney, and spleen [4,5]. Interestingly EC-SOD, via its C-
terminal domain, binds to glycosaminoglycans, such as
heparan sulfate and heparin [6-9]. We have previously
shown that cationic AMPs, including cathelicidins and
defensins, may interact with negatively charged gly-
cosaminoglycans (GAGs) like heparin [10]. Conversely,
we have demonstrated that heparin-binding motifs
[11,12], as well as peptide sequences of endogenous pro-
teins including peptides derived from complement
[13,14], human kininogen [15], matrix proteins [16],
growth factors [17], and histidine-rich glycoprotein
[18,19], all exhibit antimicrobial effects, thus acting as
"classical" peptides and proteins of innate immunity.
These observations prompted us investigate possible anti-
microbial effects of the C-terminal heparin binding
domain of EC-SOD. We here identify such an activity, and
define it in terms of action on various microbes and on
eukaryotic cells, as well as the influence on these effects of
plasma and the ionic environment.
Materials
Peptides and bacteria
The peptides RQA21 (RQAREHSERKKRRRESECKAA) and
LL-37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRN-
LVPRTES) were from Innovagen AB, Lund, Sweden. The
purity (>95%) and molecular weight of these peptides
was confirmed by mass spectral analysis (MALDI.TOF
Voyager). Escherichia coli ATCC 25922 and clinical isolate
37.4,  Pseudomonas aeruginosa ATCC 27853 and clinical
isolate 27.5, Staphylococcus aureus ATCC 29213 and clini-
cal isolate 4, Bacillus subtilis ATCC 6633, and Candida albi-
cans ATCC 90028 were all obtained from the Department
of Clinical Bacteriology at Lund University Hospital.
Radial diffusion assay
This was performed according to procedures described
previously [20]. 6 μl of test sample (100 μM) was added
to each well and for comparison, LL-37 was used.
Viable-count analysis
E. coli 37.4 were subjected to peptides at 30 and 60 μM in
10 mM Tris, with or without 0.15 M NaCl as previously
described [20].
Hemolysis and LDH assay
These assays were preformed according to procedures
described previously [17,20].
Liposome preparation and leakage assay
The liposomes investigated were anionic (DOPE/DOPG
75/25 mol/mol). DOPG (1,2-Dioleoyl-sn-Glycero-3-
Phosphoglycerol, monosodium salt) and DOPE (1,2-dio-
leoyl-sn-Glycero-3-phoshoethanolamine) were from
Avanti Polar Lipids (Alabaster, USA) and of >99% purity.
Leakage assay was performed according to previously
published procedures [20]. A SPEX-fluorolog 1650 0.22-
m double spectrometer (SPEX Industries, Edison, USA)
was used for the liposome leakage assay. Measurements
were performed in triplicate at 37°C.
Results
To investigate whether RQA21 posses antimicrobial activ-
ity, we tested the peptide against a microbe panel consist-
ing of Gram-positive and Gram-negative bacteria, as well
as yeast. The results showed that the peptides were anti-
bacterial in radial diffusion assays (RDA) against the
Gram-negative  Escherichia coli and  Pseudomonas aerugi-
nosa, the Gram-positive Bacillus subtilis and Staphylococcus
aureus, as well as the fungal isolate Candida albicans (Fig-
ure 1A). Although variability in the different sensitivities
was noted, the zone of inhibition results were lower than
those observed for the benchmark antimicrobial peptide
LL-37. Interestingly, it was observed that the two clinical
Gram-negative isolates (E. coli and P. aeruginosa) were par-
ticularly sensitive to RQA21.
It is well-known that activities of AMPs are dependent of
the microenvironment. For example, various chemokines,
defensins, as well as LL-37, are partly or completely,
antagonized by high salt conditions or the presence of
plasma proteins in vitro [21,22]. We therefore examined
the influence of physiological salt (0.15 M NaCl) on the
antimicrobial activity of RQA21 against E. coli 37.4 using
viable count analysis. As shown in Figure 1B, RQA21 effi-
ciently killed E. coli, at both 30 and 60 μM in 10 mM Tris
buffer. However, at physiological salt conditions the pep-
tide exerted no detectable antimicrobial activity (Figure
1B). This contrasted to LL-37, which was active under
both conditions. In order to explore the effect of plasmaBMC Research Notes 2009, 2:136 http://www.biomedcentral.com/1756-0500/2/136
Page 3 of 6
(page number not for citation purposes)
on the activity of RQA21, different concentrations of cit-
rate plasma (0, 50, 98%) was added to the peptides and
activity assayed using RDA (Figure 1C). The activity
decreased proportionately with an increase in the plasma
concentration, similar effects being observed for the
benchmark LL-37.
To shed some further light on RQA21, toxicity studies
against human erythrocytes and keratinocytes were per-
formed, with no hemolytic activity detected at doses of 3–
60 μM (Figure 1D, left panel). This contrasted to the anti-
microbial peptide LL-37, which permeabilised erythro-
cytes at doses >6 μM. Analogously, RQA21 did not
Activities of selected peptides Figure 1
Activities of selected peptides. (A) Antimicrobial activity of RQA21 and LL37 peptides (at 100 μM in RDA) against the 
indicated microbes. Bacteria (4 × 106 cfu) or C. albicans ATCC 90028 (1 × 105) was inoculated in 0.1% TSB agarose gel. The 
zones of clearance correspond to the inhibitory effect of each peptide (6 μl at 100 μM) after incubation at 37°C for 18–24 h 
(mean values are presented, n = 3). (B) 2 × 106 colony-forming units/ml of E. coli 37.4 bacteria were incubated in 50 μl with 
peptides at 30 and 60 μM for 2 hours followed by plating on TSB agar plates and cfu were determined. Upper panel; in 10 mM 
Tris, pH 7.4, 5 mM glucose, lower panel; the same buffer with 0.15 M NaCl. (C) Antimicrobial activity of RQA21 and LL37 
peptides (at 100 μM in RDA) against E. coli 37.4 in the presence of citrate plasma at the indicated concentrations. (D) Left 
panel; Analysis of hemolytic effects of RQA21 peptide and comparison with LL-37. The cells were incubated with peptides at 
the indicated concentrations (x-axis). 2% Triton X-100 (Sigma-Aldrich) served as positive control. The absorbance of hemo-
globin release was measured at λ 550 nm and is expressed as % of Triton X-100 induced hemolysis (y-axis) (n = 3, mean values 
and SD is indicated). Right panel; HaCaT keratinocytes were subjected to RQA21 and LL-37. Cell permeabilizing effects were 
measured by the LDH based TOX-7 kit.BMC Research Notes 2009, 2:136 http://www.biomedcentral.com/1756-0500/2/136
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permeabilise human epithelial cells (HaCaT keratinocyte
cell line), whereas LL-37 exerted permeabilising activity at
doses of 30–60 μM (Figure 1D, right panel). Additionally,
RQA21 and LL-37 both permeabilised model lipid mem-
branes at 1 μM. In parallel to the bactericidal results, LL-
37 was the more potent of the two peptides in respect to
liposome permeabilisation (Figure 2). Kinetic analysis
showed that ~80% of the maximal release caused by each
peptide occurred within 5–10 minutes for both LL-37 and
RQA21 (Figure 2).
Discussion
The findings in this report, showing that a peptide seg-
ment of EC-SOD exerts antimicrobial activities, further
underscore that endogenous proteins may harbour cryp-
tic, antimicrobial epitopes. Table 1 exemplifies the diver-
sity of such "non-classical" antimicrobial peptides,
originating from diverse proteins and that originate from
sequences known to interact with glycosaminoglycans. In
the light of this, our findings indicate that a strategy based
on selection of peptides of heparin-binding human pro-
teins may prove to be fruitful in the discovery of addi-
tional novel sequences as lead candidates for the
development of AMPs based on endogenous peptides.
RQA21 (NH2-RQAREHSERKKRRRESECKAA-COOH), is
rich in basic amino acids, with a net charge of +6 at pH
7.4, and is also strongly hydrophilic having a low relative
hydrophobic moment (0.24, Kyte & Doolittle scale, see
http://www.bbcm.univ.trieste.it/~tossi/HydroCalc/
HydroMCalc.html. Previous investigations of the struc-
ture of the C-terminal part of SOD indicate that the pep-
tide region may assume helical structures, and that
arginine side chains take part in the binding to heparin.
However, the analysis also suggested that this peptide
region exist in an equilibrium between different confor-
mations, where helical as well as random structures are
likely to be present [6]. Thus, considering the low hydro-
phobicity of RQA21, the peptide likely resembles other
linear peptides having a low helical content. For example,
AMPs derived from growth factors display a low helical
content in buffer and in presence of membranes, reflect-
ing their low content of features typical of "classical" hel-
ical peptides, such as regularly interspersed hydrophobic
residues [17]. Furthermore, studies utilizing ellipsometry,
CD, fluorescence spectroscopy, and z-potential measure-
ments on a kininogen-derived antimicrobial peptide,
HKH20 (HKHGHGHGKHKNKGKKNGKH) [23] showed
that the HKH20 peptide display primarily random coil
conformation in buffer and at lipid bilayers, the interac-
tions dominated by electrostatics, as evidenced by
strongly reduced adsorption and membrane rupture at
high ionic strength [23]. Interestingly, both HKH20 [15]
and GKR22 (GKRKKKGKGLGKKRDPCLRKYK) [17], a
peptide derived from heparin-binding growth factor,
retain antibacterial activity in physiological buffers as well
as in plasma. In contrast to these observations, RQA21
lost its antibacterial activity at high salt concentrations,
illustrating the well-known fact that cationicity alone is
not a sufficient parameter for determining antimicrobial
activity of a given peptide, and exemplifying that amphip-
athicity, as well as hydrophobicity, enabling bacterial
membrane interactions, are necessary for activity of many
AMPs [1], especially at physiological salt concentrations,
where initial electrostatic interactions with anionic cell
wall components are diminished by the ionic environ-
ment. Clearly, AMPs and other antimicrobial proteins are
dependent of the microenvironment, and may be also
antagonized the presence of plasma proteins in vitro
[17,19,21,22]. Nevertheless, there is now convincing evi-
dence that AMPs contribute to enhanced bacterial killing
in vivo, likely reflecting the necessity of AMP compartmen-
talization (diminishing toxic effects on nearby eukaryotic
cells), presence of ionic microenvironments, or synergism
between AMPs, as well as their additional roles as
immune modifiers [24].
Bacterial surfaces contain many anionic components,
including LPS and anionic lipids of Gram-negative bacte-
ria, as well as teichoic and teichuronic acids of Gram-pos-
itive bacteria. Beyond the outer cell surface, AMPs interact
with the plasma membrane. Contrasting to eukaryotic
membranes, which contain mostly zwitterionic lipids
(e.g., phosphatidylcholine), and sterols, bacterial mem-
branes comprise various acidic phospholipids (phos-
phatidylglycerol, phosphatidylserine and cardiolipin),
which confer a negative charge facilitating AMP binding
and sometimes also defect formation [25,26]. Further-
more, it has also become increasingly clear that AMP
selectivity may also depend on factors such as AMP oli-
Effects of RQA21 and LL-37 on liposome leakage kinetics Figure 2
Effects of RQA21 and LL-37 on liposome leakage 
kinetics. The membrane permeabilizing effect of the indi-
cated peptides (at 1 μM) was recorded by measuring fluores-
cence release of carboxyfluorescein from liposomes.BMC Research Notes 2009, 2:136 http://www.biomedcentral.com/1756-0500/2/136
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gomerisation and preassembly (in solution and mem-
brane) [27]. Clearly, all these factors determine the
ultimate activity of a given AMP under specific conditions.
Although high AMP activity can sometimes be reached by
highly charged and hydrophilic AMPs [15,17], Gram-pos-
itive pathogens such as Staphylococcus aureus have a rela-
tively low electrostatic surface potential, which may be
reduced or even reversed, e.g., by L-lysine modification of
phosphatidylglycerol, and D-alanine modification of cell
wall teichoic acid, reducing AMP binding to Gram-posi-
tive bacteria, respectively [28]. Likely, these mechanisms,
together with the high electronegativity of LPS, explain
the herein noted higher sensitivity of the two clinical
Gram-negative isolates (E. coli and P. aeruginosa) to the
cationic RQA21.
It is well established that SOD serves a key antioxidant
role. Mice lacking SOD2 die within days after birth due to
massive oxidative stress [29]. In contrast, mice lacking
SOD3 (EC-SOD) have a reduced life-span, although not
otherwise showing any obvious defects during devlop-
ment and early adulthood [30]. Currently, no data are
available on the immune status and infection sensitivity
of these mice. Clearly, and as mentioned above, caution
should be executed when assigning possible functional
roles for peptides based on their in vitro activities only.
However, our observation, apart from providing a link
between heparin-binding peptides and AMP activity in
vitro, raises the hypothesis that proteolytically generated
C-terminal SOD-derived peptides could interact with, and
possibly counteract bacteria in vivo. Further studies are
merited in order to investigate proteolysis of SOD, possi-
ble release of C-terminal peptides, and their potential bio-
active roles under physiological conditions.
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